Effect of sodium valproate on aripiprazole pharmacokinetics and initial dosage optimization in bipolar disorder

Figure 7 Probability within the therapeutic window range of aripiprazole in patients receiving bipolar disorder with sodium valproate sustained-release tablets. A: Patients with bipolar disorder receiving sodium valproate sustained-release tablets were simulated to receive an aripiprazole dosage of (A) 0.1 mg/kg, (B) 0.2 mg/kg, (C) 0.3 mg/kg, (D) 0.4 mg/kg, (E) 0.5 mg/kg, (F) 0.6 mg/kg aripiprazole, (G) 0.7 mg/kg, and (H) 0.8 mg/kg.